hi all
i did a quick 'dig' at pubmed for mention of olanzapine and parkinson
and came up with these abstracts of published articles
if you want to look at them at pubmed yourself at:
http://www.ncbi.nlm.nih.gov/PubMed/
use the PMID [pubmed identification number]
in the search window to go directly
to the abstract that you want
your cyber-ring-sib-ling
janet
janet paterson
51/10 - sinemet/selegiline/prozac
almonte/ontario/canada - [log in to unmask]
------------------------------------------------------------
TITLE: Olanzapine in the treatment of dopaminomimetic psychosis in patients
with Parkinson's disease.
------------------------------------------------------------
ABSTRACT: We studied the effect of olanzapine (1 to 15 mg/d) in 15 nondemented
parkinsonian patients with drug-induced psychosis.
Psychotic symptoms decreased significantly during treatment, and there was no
worsening of extrapyramidal symptoms.
These results suggest that olanzapine is a well-tolerated and effective
treatment for drug-induced psychosis in nondemented patients with Parkinson's
disease.
Neurology 1996 Oct;47(4):1085-1087
Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL
Graduate School of Neurosciences Amstordam, The Netherlands.
PMID: 8857751, UI: 97010718
------------------------------------------------------------
TITLE: Safety of olanzapine.
------------------------------------------------------------
ABSTRACT: Clinical safety data for treatment of acute schizophrenia with
olanzapine, a new atypical antipsychotic agent, are summarized.
The primary clinical trial safety database included 2500 patients treated with
olanzapine, 810 with haloperidol, and 236 with placebo.
The overall discontinuation rate from olanzapine treatment was low.
Significant adverse events included somnolence, weight gain, and asymptomatic
treatment-emergent transaminase elevation.
Minimal parkinsonism and akathisia with rare dystonia were noted.
No hematotoxicity was noted.
The incidence of seizures and sexual dysfunction was rare.
J Clin Psychiatry 1997;58 Suppl 10:13-17
Beasley CM Jr, Tollefson GD, Tran PV
Psychopharmacology Division, Eli Lilly and Company.
PMID: 9265911, UI: 97410800
------------------------------------------------------------
TITLE: The relationship of pharmacology to side effects.
------------------------------------------------------------
ABSTRACT: Most traditional neuroleptics have a narrow therapeutic-to-toxic
index, and thus, the novel antipsychotics are the result of a search to
substantially widen the distance between the dose that treats psychosis and
the one that produces adverse effects.
In vitro binding profiles have been created for the atypical antipsychotics
that have been approved by the U.S. Food and Drug Administration
(FDA)-clozapine, olanzapine, and risperidone and those that are under FDA
review-quetiapine and sertindole.
These profiles, which were compared with that of the typical neuroleptic
haloperidol, provide guidance for predicting the adverse effects produced by
these drugs.
Most conventional antipsychotics have central nervous system effects,
particularly extrapyramidal symptoms (EPS) and tardive dyskinesia, sedation,
and dulling of cognition.
Other adverse effects of the typical antipsychotics include the neuroleptic
malignant syndrome, orthostatic hypotension, changes in liver function,
anticholinergic and antiadrenergic side effects, sexual dysfunction, and
weight gain.
The newer agents have a lower incidence of EPS and tardive dyskinesia, while
weight gain and changes in blood pressure and liver function tests are adverse
effects that have been associated with the use of the newer agents.
The favorable side effect profile of these new antipsychotics is likely to
make patients more willing to continue treatment, and thus these agents
represent a step forward in the treatment of patients with severe, chronic
mental illness.
J Clin Psychiatry 1997;58 Suppl 10:55-62
Casey DE
Veterans Affairs Medical Center, Portland, OR 97207, USA.
PMID: 9265918, UI: 97410807
------------------------------------------------------------
